华特达因：子公司签署褪黑素颗粒总经销合同

Core Insights - The company announced a distribution agreement with Japan's Nobelpharma for melatonin granules, making it the exclusive distributor in mainland China [1] - The product, Manlejing®, is approved for use in children aged 6-15 with neurodevelopmental disorders to aid sleep difficulties [1] - The partnership has a duration of 10 years, with the option to renew after the term [1] Company Summary - Beijing Dainkang Health Pharmaceutical Co., Ltd., a subsidiary of the company, will handle the import, marketing, and sales of the product [1] - The agreement positions the company to tap into the growing market for pediatric sleep aids in China [1] Industry Context - The collaboration highlights the increasing demand for specialized pharmaceutical products targeting neurodevelopmental disorders in children [1] - The approval and distribution of melatonin products reflect a broader trend in the healthcare industry focusing on pediatric health solutions [1]